Clear Cell Renal Carcinoma
11
2
2
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
9.1%
1 terminated out of 11 trials
87.5%
+0.9% vs benchmark
18%
2 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (11)
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
TroVax Renal Immunotherapy Survival Trial
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE
Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project
AMG 172 First in Human Study in Patients With Kidney Cancer
Rotating Pazopanib and Everolimus to Avoid Resistance